All In Biotech

NDA 012209 · Spectrum Pharms

Fluorouracil

Fluorouracil · Injection

NovelPriority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jul 29, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1962

Apr 25, 1962

Approved uses

2

Original approval plus efficacy supplements

Registered trials

4,755

1,167 Phase 3, 630 recruiting

FAERS reports

77,613

73,672 serious, 10,971 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 29, 2016 Supplement 40 · Efficacy LetterLabel
  • Apr 25, 1962 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • FLUOROURACIL · FLUOROURACIL 2.5GM/50ML (50MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • FLUOROURACIL · FLUOROURACIL 500MG/10ML (50MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluorouracil" as an intervention, any sponsor and status, largest first.

All 4,755 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea7,077
  • neutropenia5,294
  • nausea5,064
  • vomiting4,038
  • off label use3,620
  • neuropathy peripheral3,541
  • fatigue3,320
  • disease progression3,293
  • pyrexia3,085
  • thrombocytopenia3,036
  • febrile neutropenia2,915
  • anaemia2,610

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,695
20051,687
20061,392
20071,586
20081,848
20091,815
20101,692
20112,338
20122,862
20132,240
20141,878
20152,385
20162,753
20173,198
20184,845
20195,110
20204,266
20214,273
20225,711
20236,300
20245,981
20256,681
20265,077

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fluorouracil* (Fluorouracil)

2024 spending

$45.6M

Beneficiaries

583,453

677,948 claims

Per beneficiary

$78

$1.75 per unit

View as table
YearSpending
2020$48,774,660
2021$52,372,839
2022$55,041,064
2023$52,836,157
2024$45,569,059

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8,452 on PubMed

Sponsor: Spectrum Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.